Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ATRS's Cash to Debt is ranked higher than
96% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. ATRS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ATRS' s 10-Year Cash to Debt Range
Min: 0.01  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.85
ATRS's Equity to Asset is ranked higher than
87% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ATRS: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
ATRS' s 10-Year Equity to Asset Range
Min: -4.09  Med: 0.60 Max: 0.95
Current: 0.85
-4.09
0.95
Interest Coverage No Debt
ATRS's Interest Coverage is ranked higher than
93% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.79 vs. ATRS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ATRS' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: 8.57
M-Score: -0.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -67.35
ATRS's Operating margin (%) is ranked lower than
87% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. ATRS: -67.35 )
Ranked among companies with meaningful Operating margin (%) only.
ATRS' s 10-Year Operating margin (%) Range
Min: -1709.11  Med: -193.93 Max: -26.96
Current: -67.35
-1709.11
-26.96
Net-margin (%) -67.71
ATRS's Net-margin (%) is ranked lower than
86% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. ATRS: -67.71 )
Ranked among companies with meaningful Net-margin (%) only.
ATRS' s 10-Year Net-margin (%) Range
Min: -1728.74  Med: -189.78 Max: -26.66
Current: -67.71
-1728.74
-26.66
ROE (%) -49.23
ATRS's ROE (%) is ranked lower than
86% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. ATRS: -49.23 )
Ranked among companies with meaningful ROE (%) only.
ATRS' s 10-Year ROE (%) Range
Min: -6852.6  Med: -102.58 Max: -19.42
Current: -49.23
-6852.6
-19.42
ROA (%) -33.87
ATRS's ROA (%) is ranked lower than
85% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. ATRS: -33.87 )
Ranked among companies with meaningful ROA (%) only.
ATRS' s 10-Year ROA (%) Range
Min: -530.86  Med: -59.93 Max: -15.37
Current: -33.87
-530.86
-15.37
ROC (Joel Greenblatt) (%) -218.99
ATRS's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. ATRS: -218.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2034.35  Med: -912.74 Max: -394.95
Current: -218.99
-2034.35
-394.95
Revenue Growth (3Y)(%) 5.60
ATRS's Revenue Growth (3Y)(%) is ranked higher than
54% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ATRS: 5.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ATRS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -63.4  Med: 8.15 Max: 89.8
Current: 5.6
-63.4
89.8
EBITDA Growth (3Y)(%) 86.60
ATRS's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. ATRS: 86.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ATRS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -41.9  Med: -13.10 Max: 86.6
Current: 86.6
-41.9
86.6
EPS Growth (3Y)(%) 75.40
ATRS's EPS Growth (3Y)(%) is ranked higher than
95% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ATRS: 75.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ATRS' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.1  Med: -12.95 Max: 75.4
Current: 75.4
-58.1
75.4
» ATRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ATRS Guru Trades in Q3 2014

Jim Simons 145,728 sh (New)
First Eagle Investment 20,000 sh (unchged)
» More
Q4 2014

ATRS Guru Trades in Q4 2014

First Eagle Investment 20,000 sh (unchged)
Jim Simons 85,970 sh (-41.01%)
» More
Q1 2015

ATRS Guru Trades in Q1 2015

First Eagle Investment 20,000 sh (unchged)
Jim Simons Sold Out
» More
Q2 2015

ATRS Guru Trades in Q2 2015

Jim Simons 182,941 sh (New)
First Eagle Investment 20,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ATRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 35.84
ATRS's Forward P/E is ranked lower than
80% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.74 vs. ATRS: 35.84 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.58
ATRS's P/B is ranked lower than
58% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. ATRS: 3.58 )
Ranked among companies with meaningful P/B only.
ATRS' s 10-Year P/B Range
Min: 2.5  Med: 8.09 Max: 77.5
Current: 3.58
2.5
77.5
P/S 6.63
ATRS's P/S is ranked lower than
81% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. ATRS: 6.63 )
Ranked among companies with meaningful P/S only.
ATRS' s 10-Year P/S Range
Min: 3.56  Med: 13.00 Max: 36
Current: 6.63
3.56
36
Current Ratio 4.82
ATRS's Current Ratio is ranked higher than
82% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. ATRS: 4.82 )
Ranked among companies with meaningful Current Ratio only.
ATRS' s 10-Year Current Ratio Range
Min: 0.11  Med: 3.13 Max: 17.17
Current: 4.82
0.11
17.17
Quick Ratio 4.41
ATRS's Quick Ratio is ranked higher than
84% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. ATRS: 4.41 )
Ranked among companies with meaningful Quick Ratio only.
ATRS' s 10-Year Quick Ratio Range
Min: 0.09  Med: 3.03 Max: 16.5
Current: 4.41
0.09
16.5
Days Inventory 150.14
ATRS's Days Inventory is ranked lower than
63% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. ATRS: 150.14 )
Ranked among companies with meaningful Days Inventory only.
ATRS' s 10-Year Days Inventory Range
Min: 11.13  Med: 36.33 Max: 200.11
Current: 150.14
11.13
200.11
Days Sales Outstanding 62.38
ATRS's Days Sales Outstanding is ranked higher than
52% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. ATRS: 62.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATRS' s 10-Year Days Sales Outstanding Range
Min: 15.98  Med: 48.34 Max: 266.58
Current: 62.38
15.98
266.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.78
ATRS's Price/Net Cash is ranked higher than
71% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.72 vs. ATRS: 7.78 )
Ranked among companies with meaningful Price/Net Cash only.
ATRS' s 10-Year Price/Net Cash Range
Min: 1.18  Med: 12.64 Max: 135.5
Current: 7.78
1.18
135.5
Price/Net Current Asset Value 5.42
ATRS's Price/Net Current Asset Value is ranked higher than
62% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.89 vs. ATRS: 5.42 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATRS' s 10-Year Price/Net Current Asset Value Range
Min: 0.89  Med: 9.11 Max: 54
Current: 5.42
0.89
54
Price/Tangible Book 3.73
ATRS's Price/Tangible Book is ranked higher than
56% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. ATRS: 3.73 )
Ranked among companies with meaningful Price/Tangible Book only.
ATRS' s 10-Year Price/Tangible Book Range
Min: 0.62  Med: 7.66 Max: 44.5
Current: 3.73
0.62
44.5
Price/Median PS Value 0.51
ATRS's Price/Median PS Value is ranked higher than
89% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. ATRS: 0.51 )
Ranked among companies with meaningful Price/Median PS Value only.
ATRS' s 10-Year Price/Median PS Value Range
Min: 0.08  Med: 0.80 Max: 2.49
Current: 0.51
0.08
2.49
Earnings Yield (Greenblatt) (%) -11.10
ATRS's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ATRS: -11.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATRS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -14.65  Med: 0.00 Max: 0
Current: -11.1
-14.65
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 43 66 91
EPS($) -0.11 0.05 0.09
EPS without NRI($) -0.11 0.05 0.09

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:MJC.Germany,
Antares Pharma Inc was incorporated on February 1979. The Company is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies. It develops & manufactures novel, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. The Company has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It also developed a disposable multi-dose pen injector for use with standard cartridges. The Company developed the Vibex auto injector for its product OTREXUP. The Company has launched OTREXUP injection, subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. The Company is conducting clinical studies of Vibex QS T, for testosterone replacement therapy. It is also developing VIBEX Sumatriptan for the acute treatment of migraines. The Company's development projects include VIBEX epinephrine, an exenatide multi-dose pen, and another undisclosed multi-dose pen. The Company also makes a reusable, needle-free, spring-action injector device known as the Tjet and Zomajet, which is marketed for use with human growth hormone. The Company also has a portfolio of gel-based products inclduing Gelnique for the treatment of overactive bladder. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, Novartis, Mylan, Roxane, Bedford Labs, Hospira, and Accord Healthcare. Any potential products discovered, developed and manufactured by the Company must comply with comprehensive regulation by the FDA in the U.S. and by comparable authorities in other countries.
» More Articles for ATRS

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

More From Other Websites
ANTARES PHARMA, INC. Financials Aug 21 2015
10-Q for Antares Pharma, Inc. Aug 12 2015
Edited Transcript of ATRS earnings conference call or presentation 10-Aug-15 12:30pm GMT Aug 10 2015
Antares Pharma reports 2Q loss Aug 10 2015
Q2 2015 Antares Pharma Inc Earnings Release - Before Market Open Aug 10 2015
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 10 2015
Antares Pharma Reports Second Quarter 2015 Operating and Financial Results Aug 10 2015
Antares Pharma Announces First Patients Enrolled In QuickShot® Testosterone Supplemental Safety... Aug 04 2015
Antares Pharma to Host Second Quarter 2015 Operating and Financial Results Conference Call Aug 03 2015
Searching for Value in a Beaten Down Sector Jul 30 2015
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jul 16 2015
Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human... Jul 14 2015
Deerfield Management Trims Holding In Antares Pharma Inc (ATRS) Just Before Disastrous Setback Jun 17 2015
Antares Pharma to Present at the JMP Securities Life Sciences Conference Jun 16 2015
Earnings Estimates Moving Higher for Antares (ATRS): Time to Buy? - Tale of the Tape Jun 08 2015
Sell These 7 Health Care Supplies Companies Now Jun 04 2015
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 03 2015
Analyst Offers Top US Growth Stock Calls for This Week Jun 02 2015
ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 01 2015
Antares Pharma Announces Additional Update to QuickShot Testosterone Program Jun 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK